<DOC>
	<DOCNO>NCT00077467</DOCNO>
	<brief_summary>This phase I trial study side effect best dose bortezomib treat young patient refractory recurrent leukemia . Bortezomib may stop growth cancer cell block enzymes necessary growth .</brief_summary>
	<brief_title>Bortezomib Treating Young Patients With Refractory Recurrent Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary I . Determine maximum tolerate dose recommended phase II dose bortezomib child refractory recurrent leukemia . II . Determine toxic effect drug patient . III . Determine pharmacokinetics drug patient . Secondary I . Determine , preliminarily , antitumor activity drug patient . II . Determine , preliminarily , biologic activity drug patient . OUTLINE : This dose-escalation , open-label , multicenter study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 3-36 patient accrue study within 1.5-36 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm leukemia 1 follow type : Acute lymphoblastic leukemia Acute myeloid leukemia Chronic myelogenous leukemia blast crisis Relapsed refractory disease Immunophenotypically confirm disease , either initial diagnosis relapse More 25 % blast bone marrow ( M3 bone marrow ) Active extramedullary disease ( except leptomeningeal disease ) allow No know curative therapy therapy proven prolong survival acceptable quality life available Performance status Karnofsky 50100 % ( patient age 11 21 ) Performance status Lansky 50100 % ( patient age 10 ) Platelet count ≥ 20,000/mm^3* Hemoglobin ≥ 8.0 g/dL* WBC &lt; 20,000/mm^3** ( hydroxyurea cytoreduction allow ) No hyperleukocytosis ( i.e. , WBC &gt; 100,000/mm^3 ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 5 time ULN Albumin ≥ 2 g/dL Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min Creatinine base age follow : ≤ 0.8 mg/dL patient age 5 ≤ 1.0 mg/dL patient age 6 10 ≤ 1.2 mg/dL patient age 11 15 ≤ 1.5 mg/dL patient age 16 21 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection Recovered prior immunotherapy At least 7 day since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) At least 7 day since prior biologic agent At least 3 month since prior stem cell transplantation rescue evidence active graftversushost disease No concurrent prophylactic GCSF course 1 study No concurrent immunotherapy No concurrent biologic therapy Recovered prior chemotherapy At least 24 hour since prior hydroxyurea cytoreduction At least 6 week since prior nitrosoureas No concurrent chemotherapy At least 7 day since prior steroid ( except premedication prior blood product transfusion ) Recovered prior radiotherapy At least 2 week since prior small port local palliative radiotherapy At least 3 month since prior total body irradiation , craniospinal irradiation , irradiation 50 % pelvis At least 6 week since prior substantial bone marrow radiotherapy No concurrent radiotherapy At least 7 day since prior retinoids No concurrent investigational agent No concurrent anticancer agents No concurrent anticonvulsant medication know activate cytochrome p450 system ( e.g. , phenytoin , carbamazepine , phenobarbital ) Concurrent benzodiazepines gabapentin allow</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>